Latest filings (excl ownership)
25-NSE
Exchange delisting
25 Apr 24
8-K
Bankruptcy or Receivership
22 Apr 24
8-K/A
Other Events
11 Apr 24
8-K/A
Other Events
5 Apr 24
8-K/A
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
28 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update
27 Mar 24
8-K
Departure of Directors or Certain Officers
15 Mar 24
8-K
Gamida Cell Actively Pursuing Strategic Alternatives
29 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Departure of Directors or Certain Officers
18 Dec 23
EFFECT
Notice of effectiveness
15 Dec 23
CORRESP
Correspondence with SEC
13 Dec 23
S-3/A
Shelf registration (amended)
6 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 Nov 23
S-3
Shelf registration
15 Nov 23
8-K
Departure of Directors or Certain Officers
15 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update
14 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
20 Oct 23
DEFA14A
Additional proxy soliciting materials
11 Oct 23
DEFA14A
Additional proxy soliciting materials
29 Sep 23
8-K
Regulation FD Disclosure
27 Sep 23
DEF 14A
Definitive proxy
13 Sep 23
PRE 14A
Preliminary proxy
1 Sep 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update
14 Aug 23
8-K
Gamida Cell Appoints Terry Coelho as CFO
22 May 23
8-K
Amendments to Articles of Incorporation or Bylaws
19 May 23
S-8
Registration of securities for employees
16 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Gamida Cell Reports First Quarter 2023 Financial Results and Provides Company Update
15 May 23
DEFR14A
Revised proxy
9 May 23
8-K
Gamida Cell Announces Launch of Public Offering of Securities
21 Apr 23
424B5
Prospectus supplement for primary offering
20 Apr 23
DEF 14A
Definitive proxy
20 Apr 23
424B5
Prospectus supplement for primary offering
19 Apr 23
8-K
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
17 Apr 23
PRE 14A
Preliminary proxy
7 Apr 23
10-K
2022 FY
Annual report
31 Mar 23
Latest ownership filings
SC 13G/A
LEVIN CAPITAL STRATEGIES, L.P.
1 Apr 24
SC 13G/A
CVI Investments, Inc.
14 Feb 24
SC 13G/A
Rock Springs Capital Management LP
14 Feb 24
SC 13G/A
Stonepine Capital Management, LLC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G
LEVIN CAPITAL STRATEGIES, L.P.
8 Feb 24
4
KENNETH I MOCH
2 Feb 24
4
STEPHEN T WILLS
2 Feb 24
4
Shawn Tomasello
2 Feb 24
4
JULIAN ADAMS
2 Feb 24
4
Ronit Simantov
2 Feb 24
4
Ivan M. Borrello
2 Feb 24
4
Joshua F. Patterson
2 Feb 24
4
Michele Ilene Korfin
2 Feb 24
SC 13G/A
HIGHBRIDGE CAPITAL MANAGEMENT LLC
2 Feb 24
SC 13D/A
AI Gamida Holdings LLC
20 Nov 23
SC 13D/A
Community US Fund Management, Inc.
8 Nov 23
4
Abigail L. Jenkins
20 Oct 23
4/A
Shawn Tomasello
20 Oct 23
4/A
Shawn Tomasello
20 Oct 23
4/A
STEPHEN T WILLS
20 Oct 23
4/A
Ivan M. Borrello
20 Oct 23
4/A
Abigail L. Jenkins
20 Oct 23
4/A
KENNETH I MOCH
20 Oct 23
4/A
JULIAN ADAMS
20 Oct 23
SC 13D/A
AI Gamida Holdings LLC
2 Oct 23
SC 13G
Stonepine Capital Management, LLC
24 Aug 23
SC 13D
Community US Fund Management, Inc.
21 Aug 23
4
Jeremy Blank
15 Aug 23
3
Jeremy Blank
15 Aug 23
4
Mary Theresa Coelho
14 Jun 23
SC 13D/A
NOVARTIS PHARMA AG
26 May 23
3
Mary Theresa Coelho
25 May 23
SC 13G
Stonepine Capital Management, LLC
1 May 23
SC 13D/A
AI Gamida Holdings LLC
25 Apr 23
SC 13G
CVI Investments, Inc.
24 Apr 23
SC 13D/A
AI Gamida Holdings LLC
4 Apr 23
4
Shawn Tomasello
22 Mar 23
SC 13D/A
NOVARTIS PHARMA AG
3 Mar 23
SC 13G
Community US Fund Management, Inc.
14 Feb 23